ClinicalTrials.Veeva

Menu

Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins (BOHEM)

N

Nantes University Hospital (NUH)

Status

Completed

Conditions

Osteopenia
Hemophilia
Arthropathy

Treatments

Other: Observational study

Study type

Observational

Funder types

Other

Identifiers

NCT04206033
RC19_0446

Details and patient eligibility

About

The investigators propose, as part of the study, to carry out for each patient:

  • An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115, CCR2, CX3CR1, CD163 and CD206).
  • A population assessment of Myeloid-Derived Suppressor Cells (MDSC).
  • Assays of cytokines and chemokines involved in inflammation by multiplex analyzes: Il-1 (α and β), Il-4, Il-6, Il-10, Il-13, TNF- α, TGF- β, CRP , leptin, IFN- β.
  • Specialized dosages of proteins involved in bone metabolism. RANKL, osteoprotegerin, M-CSF, TRAPCP5.

Enrollment

73 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Major patients followed at the hemophilia treatment reference center,
  • Presenting the diagnosis of severe, moderate or minor Hemophilia A / B,
  • Having a social security system,
  • Obtaining the oral non-objection collection from the patient after information.

Exclusion criteria

  • Minor patients, under guardianship or curatorship.

  • Causes of secondary osteoporosis:

    • Systemic corticosteroid therapy in progress (≥ 3 consecutive months, at a dosage ≥ 7.5 mg / d of prednisone equivalent).
    • other treatment or condition responsible for osteoporosis: prolonged or medicated hypogonadism, untreated active hyperthyroidism, hypercorticism, primary hyperparathyroidism.
  • Treatment with biphosphonates, biotherapies or hormone therapy in the treatment of prostate cancer.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems